Patient-Derived Breast Cancer Organoid Model

Breast cancer (BC) is a malignant tumor disease frequently occurring in women. Over the decades, the enthusiasm for research on BC never wanes. Patient-derived BC organoid models utilize cells with differentiation capability, and supplement extracellular matrix components and cytokines to maintain stem cells growing normally by applying in vitro 3D culture technology. For research on BC, they are ideal choices. Creative Biolabs understands your BC research needs and is your trustworthy partner for the mechanism research on BC and the drug development of preclinical stages.

Fig 1. Cultivation and application of breast cancer (BC) patient-derived organoids (PDOs).¹

Shortcomings of Common Models

Standard breast disease models are mainly cells and patient-derived xenografts (PDX). Cell models are easy to handle and can adjust to cultural conditions. What leave researchers discouraged is that cross-contamination often appears. Furthermore, another troubling issue is the patient's genetic information and tumor heterogeneity, which is challenging to retain in multiple passages. PDX models can display the occurrence and evolution of tumors to a certain extent. Nevertheless, it is time-consuming, hard to construct successfully, needs a high expense, and inevitably faces ethical issues. Thus, there is an urgent need to develop novel BC research models.

Advantages of Patient-derived BC Organoid Models

With the patient number continuing to grow and the potential variations in BC's molecular phenotype and genotype, BC organoids have come along. As a more efficient and novel model, it maintains the biological characteristics of breast cancer. Compared with other standard in vitro models, tissues generated by organoid systems have a lot of unique advantages.

• Generated tissues can display relatively complex structures and functions, and similar microenvironments to BC cells.
• Cheaper and more rapid than xenografts.
• Organoid culture requires fewer tissue samples but exhibits a high success opportunity, meanwhile bypassing ethical problems and specie differences.
• BC stem cells can withstand a long-term subculture process and obtain their original differentiation ability in vitro.
• These models allow repeated sampling from patients and can predict patients' drug response to therapy.

Applications

Patient-derived BC organoid models have been demonstrated to be reliable for studying BC that promises to replace and reduce the use of animals in preclinical research. Several ongoing studies evaluated them as a platform to study new drugs' efficacy, sensitivity, and specificity. This model is suitable for studying the occurrence and evolution of BC. Moreover, BC organoids present all subtypes of solid tumors. As a feasible biological model, it has become increasingly recognized for in vitro BC studies.

Fig.2 Preclinical applications of organoid technology. (Creative Biolabs)

Related Services

Creative Biolabs is devoted to providing reliable services and high-quality patient-derived breast cancer organoid models to global customers to assist preclinical drug research projects achieve success. Don’t hesitate to contact us to discuss your project for professional assistance.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model